- Brand names:
- Pharmaceutical Company:
- Condition/Indication:
- Meeting Date: July 2018
- Public Summary Document (PSD) July 2018 PBAC Meeting - PDF
- Public Summary Document (PSD) July 2018 PBAC Meeting - Word
Nivolumab and ipilimumab (malignant melanoma) – July 2018
Nivolumab and ipilimumab (malignant melanoma): Nivolumab: Injection concentrate for I.V. infusion 40
Last updated
26 October 2018